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Lung function, COPD and cognitive function: 
a multivariable and two sample Mendelian 
randomization study
Daniel H. Higbee1,2, Raquel Granell1, Gibran Hemani1, George Davey Smith1 and James W. Dodd1,2*  
Abstract 
Background: Observational studies show an association between reduced lung function and impaired cognition. 
Cognitive dysfunction influences important health outcomes and is a precursor to dementia, but treatments options 
are currently very limited. Attention has therefore focused on identifying modifiable risk factors to prevent cognitive 
decline and preserve cognition. Our objective was to determine if lung function or risk of COPD causes reduced cog-
nitive function using Mendelian randomization (MR).
Methods: Single nucleotide polymorphisms from genome wide association studies of lung function and COPD 
were used as exposures. We examined their effect on general cognitive function in a sample of 132,452 individuals. 
We then performed multivariable MR (MVMR), examining the effect of lung function before and after conditioning for 
covariates.
Results: We found only weak evidence that reduced lung function (Beta − 0.002 (SE 0.02), p-value 0.86) or increased 
liability to COPD (− 0.008 (0.008), p-value 0.35) causes lower cognitive function. MVMR found both reduced  FEV1 and 
FVC do cause lower cognitive function, but that after conditioning for height (− 0.03 (0.03), p-value 0.29 and − 0.01 
(0.03) p-value 0.62, for FEV1 and FVC respectively) and educational attainment (− 0.03 (0.03) p-value 0.33 and − 0.01 
(0.02), p-value 0.35) the evidence became weak.
Conclusion: We did not find evidence that reduced lung function or COPD causes reduced cognitive function. Previ-
ous observational studies are probably affected by residual confounding. Research efforts should focus on shared risk 
factors for reduced lung function and cognition, rather than lung function alone as a modifiable risk factor.
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Cognitive function impacts important physical and men-
tal health outcomes including mortality and educational 
attainment [1]. It exists on a continuum from normal 
cognitive function, to the potentially reversible state 
of mild cognitive impairment (MCI), which can lead 
to irreversible dementia [2, 3]. There are very limited 
therapeutic options which effectively increase cognitive 
function or treat MCI, so finding modifiable risk factors 
is important.
Lung function measures such as Forced Expiratory 
Volume in one second  (FEV1) and Forced Expiratory Vol-
ume (FVC) have been linked with co-morbidities as early 
as the third decade [4]. There is also a growing body of 
evidence across cross sectional and longitudinal studies 
pointing to a an association between reduced lung func-
tion, Chronic Obstructive Pulmonary Disease (COPD) 
and cognitive function [5–10].
Co-morbid lung disease and cognitive impairment is 
associated with worse health outcomes, quality of life 
and increased healthcare utilisation [11]. The association 
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between lung function and cognition may be due to 
shared risk factors seen more commonly in those with 
lung disease e.g. smoking [12, 13]. However associations 
independent of these factors mediated through plausible 
causal pathological pathways such as hypoxia, hypercap-
nia or chronic lung disease associated inflammation may 
also cause extra pulmonary end organ damage [5, 14].
Neuroimaging provides further evidence of a rela-
tionship between lung function and cognition. After 
adjustment for smoking, reduced lung function remains 
associated with white matter brain lesions [15], and a 
‘dose response’ like relationship is seen between severity 
of lung function deficit and risk of cognitive impairment 
[6].
Mendelian randomization (MR) is a method which can 
overcome problems of unmeasured confounding and 
reverse causation typical of conventional observational 
epidemiology [16]. MR allows causal inference through 
the use of genetic variants as proxies for modifiable 
risk factors and health outcomes [17]. MR has multiple 
advantages, it is not influenced by behavioural or envi-
ronmental factors and minimizes reverse causation [17]. 
Additionally, the effects are equivalent to lifetime differ-
ences, reducing issues relating to transient fluctuations in 
exposures [18]. Multivariable MR (MVMR) has further 
advantages, it includes multiple exposures in the model 
(e.g. lung function and educational attainment) allowing 
estimation of the direct causal effect of each exposure 
on the outcome. MVMR is a robust method when using 
two exposures that could act as a confounders [19]. MR 
has been used in this way to show that low FVC (but not 
 FEV1) causes coronary artery disease [20].
Our objective was to use MR and MVMR to determine 
if lung function or liability to COPD causes lower gen-
eral cognitive function. If the relationship is shown to be 
causal, then interventions to treat lung function could 




The largest available lung function Genome Wide Asso-
ciation Study (GWAS) by Shrine et al. was utilised, which 
reported 279 Single Nucleotide Polymorphisms (SNPs) 
to p-value < 5 ×  10−9[21]. Lung function measurements 
used were  FEV1, FVC,  FEV1/FVC and Peak Expiratory 
Flow (PEF). The GWAS was adjusted for age,  age2, height 
and smoking status [21].
For liability to COPD, we used 82 SNPs identified from 
a GWAS of 35,735 COPD and 222,076 control subjects 
[22]. Cases were defined as those with pre-bronchodila-
tor spirometry of  FEV1/FVC < 0.7 and  FEV1 percent pre-
dicted < 80%. The GWAS was adjusted for age,  age2, sex, 
height, principal components, and smoking. These two 
GWAS were used for 2-sample MR studies (2 sample MR 
is when the exposure and outcome GWAS are from two 
different sample populations).
The lung function GWAS methodology adjust for 
covariates of lung function and cognition e.g. height and 
smoking [12, 23]. This adjustment can lead to collider 
bias as SNPs can be related to lower levels of the covari-
ates e.g. height, or to other adverse risk factors [18]. This 
can result in misleading SNP effect estimates and subse-
quent bias in MR studies [24]. To avoid these types of bias 
we performed MVMR using exposure SNPs discovered in 
GWAS that had not been adjusted for covariates. To find 
suitable exposure SNPs we performed a GWAS (adjust-
ing for sex) based on 353,315 UK BioBank (UKBB) par-
ticipants for “best measure”  FEV1 and FVC. We did not 
adjust for age as this is not genetically determined and 
allele effects are independent of age. The SNPs discov-
ered in the unadjusted GWAS were used in a two-sam-
ple MVMR model conditioning on SNPs for covariates: 
standing height, body mass index (BMI), current smok-
ing. Educational attainment is a significant determinant 
of cognitive function, but it was not adjusted for in the 
outcome GWAS [25]. Therefore, we used SNPs for a 
GWAS of the UK Biobank variable “at what age did you 
complete your continuous full time education”, hence-
forth referred to as educational attainment. Participants 
were asked this via a touchscreen during assessment. By 
conditioning for educational attainment, we determined 
the direct effect of lung function on cognitive function. 
SNPs for these covariates were found in pre-existing 
GWAS performed in the UKBB [26]. See Additional files 
1 and 2.
Outcome population
Data from a meta-analysis of the Cohort of Heart and 
Aging Research in Genomic Epidemiology (CHARGE) 
and Cognitive Genomics Consortium (COGENT) was 
used [1]. UKBiobank participants were excluded from 
our analysis to ensure no overlap of exposure and out-
come populations. This resulted in an outcome popula-
tion of 132,452. The CHARGE and COGENT cohorts 
constructed a general cognitive function phenotype a 
number of cognitive tasks. The general cognitive func-
tion phenotype required the cohorts to have tested at 
least three different cognitive domains. As different tasks 
were used across the different sample populations, a con-
sistent method of extracting general cognitive function 
was used. Principal component analysis was applied to 
the cognitive test scores to derive a measure of general 
cognitive function. The CHARGE and COGENT cohorts 
avoided taking more than one cognitive score from any 
individual cognitive test. GWAS Meta-analysis adjusting 
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for age, sex and population stratification was performed 
using the derived measure of general cognitive function. 
Therefore, the outcome used in our analysis derived from 
the CHARGE and COGENT cohorts represents general 
cognitive function and is not domain specific. For full 
details of the tasks and samples see the supplementary 
information of the reference [1].
Both exposure and outcome populations were in those 
of European ancestry. For a summary of the UK Biobank 
population please see Additional file 1: Table e4.
Statistical analysis
Statistical analysis was done using R Studio version 3.6.1 
with MRCIEU/TwoSampleMR and MRInstruments 
packages [19, 27].
An assumption of Mendelian randomization is that the 
exposure SNPs are strongly associated with the exposure 
trait, in this case lung function and COPD. If the SNPs 
are only weakly associated with their respective expo-
sure, this causes weak instrument bias and may invalidate 
the analysis. Therefore, F-statistics were calculated to 
assess exposure instruments strength (F statistic =  beta2/
standard  error2). If the F-statistic is > 10 it means weak 
instrument bias in unlikely, and the higher the F-statistic 
the lower the chance of weak instrument bias [28]. For 
all exposures SNPs LD-clumping was performed using 
European reference population and the ieugwasr:ld_
clump tool. This removes SNPs that are in close proxim-
ity (kb = 10,000), or highly correlated  (r2 0.001), to ensure 
that all SNPs used have independent effects. Steiger fil-
tering was performed, to remove variants that caused 
more variance of the outcome than the exposure [27]. 
Duplicate SNPs were removed. Palindromic SNPs (i.e. 
A/T and C/G SNPs) with intermediate allele frequen-
cies were excluded from analysis to ensure that the cor-
rect allele was being used. All SNPs were harmonised to 
ensure the exposure and outcome alleles were the same. 
See Additional files 1 and 2.
Inverse Variance Weighting (IVW) was used for main 
effect estimate for all analyses. IVW is a weighted regres-
sion of SNP-outcome on SNP-exposure associations 
combined.
MR assumptions and details of sensitivity tests used are 
detailed in the Additional files 1 and 2.
To account for the possibility of horizontal pleiot-
ropy (where SNPs influence both exposure and outcome 
through independent pathways), in the 2S-MR analysis 
we performed MR Egger. Similar to IVW, MR-Egger is 
a weighted regression of SNP-outcome on SNP-expo-
sure associations, but the intercept is not fixed to zero. 
We used weighted median and mode MR to minimise 
the effect of unbalanced instruments on an overall esti-
mate of the mean. Heterogeneity (the variability in causal 
estimates obtained for each SNP) is an indication of 
potential violation of assumptions. This was calculated 
and assessed with a Q statistic, presented as a Q_P-value. 
MR Radial was performed to identify and exclude outli-
ers and re-estimate IVW. MR radial removes SNPs that 
contribute more than 5% to the heterogeneity of the 
model [29].
IRB approval was not required as we did not recruit 
individuals but used publicly accessible data. UK Biobank 
is monitored by the UK Biobank Ethics and Governance 
Council.
Results
The analysis using the adjusted lung function GWAS in 
a 2-sample lung function analysis is reported in Table 1 
[21]. Effects are per standard deviation (SD) decrease 
in lung function measure. F statistic for all SNPs com-
bined for each lung function trait were = 111,  FEV1 = 69, 
FVC = 70,  FEV1/FVC = 148, making weak instrument 
bias unlikely. The predictive causal effects show reduced 
 FEV1 and FVC reduced cognition across all tests, but the 
evidence was weak (Table 1). All lung function measures 
combined did not show consistent direction of effect 
across the tests used. There was strong evidence of het-
erogeneity of effect based on the Q_P-value, especially 
when assessing all measures combined. However, there 
were no visual outliers (Additional file 1: Figures E1-E4) 
and minimal change in effect estimates after using MR-
Radial to exclude outliers and recalculation of IVW. See 
Additional files 1 and 2.
F statistic for COPD SNPs combined is 52, mak-
ing weak instrument bias unlikely. There is a consist-
ent direction of effect that increased liability to COPD 
causes lower cognition, however the strength of evidence 
is weak (Table  2). There was evidence of heterogeneity, 
however no outliers were identified visually (Additional 
file  1: Figures  E5-E8) and exclusion of outliers in MR-
Radial only minimally changed effect estimates.
MVMR analysis
Using a threshold of p < 5 ×  10–8, quality control and 
clumping the unadjusted GWAS of lung function in 
UKBB produced 360 SNPs for  FEV1 and 464 SNPs for 
FVC explaining 3·6% and 4·8% of variance, respectively. 
Height (Beta 0.05 (SE 0.01), p-value < 0.001), BMI (− 0.1 
(0.01), p-value < 0.001) and educational attainment (0.3 
(0.07), p-value < 0.001) showed strong evidence for an 
effect on cognitive function. The SNPs discovered in the 
GWAS of current smoking only had very weak evidence 
of effect on cognitive function (− 0.04 (0.2), p-value 0.84), 
so they were not included in the analysis. The F-statis-
tic for combined SNPs for each lung function trait are 
 FEV1 = 38, FVC = 40, standing height = 50, BMI = 39 and 
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age completed full time education = 1350, making weak 
instrument bias unlikely.
Results were calculated per SD decrease in lung func-
tion measure. There was strong evidence that reduced 
 FEV1 (− 0.06 (0.03), p-value < 0.001) and FVC (− 0.06 
(0.01), p-value < 0.001) cause lower general cognition, 
however with MVMR after conditioning with educational 
attainment the evidence became weak. Evidence also 
became weak after conditioning for height. This is prob-
ably due to the pleiotropy in the MR analysis as the unad-
justed GWAS would have discovered SNPs that affected 
LF via height or educational attainment (Table 3).
Discussion
Our analyses show weak evidence that lung function or 
liability to COPD causes lower general cognitive func-
tion. Most causal estimates show the same direction of 
Table 1 2-Sample MR, decreasing lung function effect on cognitive function
Negative beta indicates decreasing cognitive function
SE, standard error; Q_P-value, a measure of heterogeneity (p-value < 0.05 provides strong evidence of heterogeneity)
Lung function measure No. of SNPs Test used Cognitive function
Beta (SE) p-value Q_P-value
FEV1, FVC,  FEV1/FVC, PEF 173 IVW − 0.002 (0.02) 0.86 1.44 ×  1011
Weighted median 0.02 (0.02) 0.44
Weighted Mode − 0.004 (0.03) 0.91
MR Egger − 0.005 (0.03) 0.90
FEV1 59 IVW − 0.05 (0.04) 0.44 1.8 ×  10–8
Weighted median − 0.02 (0.04) 0.46
Weighted mode − 0.05 (0.08) 0.51
MR Egger − 0.09 (0.1) 0.43
FVC 68 IVW − 0.004 (0.03) 0.87 0.01
Weighted median − 0.02 (0.04) 0.51
Weighted mode − 0.03 (0.07) 0.65
MR Egger − 0.16 (0.10) 0.13
FEV1/FVC 93 IVW 0.01 (0.02) 0.52 0.01
Weighted median 0.02 (0.02) 0.52
Weighted mode 0.007 (0.05) 0.87
MR Egger 0.02 (0.04) 0.67
Table 2 2-Sample MR, COPD effect on cognitive function
Negative beta indicates decreasing cognitive function
Lung function measure No. of SNPs Test used Cognitive function
Beta (SE) p-value Q_P-value
COPD 67 IVW − 0.008 (0.008) 0.35 0.005
Weighted median − 0.01 (0.01) 0.16
Weighted mode − 0.03 (0.02) 0.28
MR Egger − 0.01 (0.02) 0.66
Table 3 MVMR analysis results
Effect of decreasing Lung function trait on cognitive function with and without 
conditioning for covariates










FEV1 None 298/0 − 0.06 (0.03) < 0.001
FEV1 Height 212/299 − 0.03 (0.03) 0.29
FEV1 BMI 180/629 − 0.07 (0.03) 0.03
FEV1 Educational 
attainment
274/32 − 0.03 (0.03) 0.33
FVC None 381/0 − 0.06 (0.01) < 0.001
FVC Height 278/314 − 0.01 (0.03) 0.62
FVC BMI 224/595 − 0.05 (0.02) 0.004
FVC Educational 
attainment
335/31 − 0.01 (0.02) 0.35
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effect as observational studies, with worse lung function, 
liability to COPD causing lower general cognitive func-
tion, however the evidence is weak. The observed asso-
ciation is likely secondary to residual confounding and 
collider bias. This would indicate that observed associa-
tions may be present but not causal [5–10].
Two-sample MR eliminates many confounders in 
observational epidemiology [17, 30]. We used a large 
number of robust lung function SNPs, and SNPs that 
influence liability to COPD, which have been well vali-
dated in large samples [21, 22]. MVMR was utilised to 
decrease the risk of bias and allowed us to condition for 
the effect of educational attainment. The effects of instru-
mental variables were assessed in a huge outcome popu-
lation of similar age and the same ancestral population as 
our discovery GWAS.
Our analysis suggest that shared risk factors are likely 
explanations for the observed association between lung 
function and cognition, for example cigarette smoking. 
The short term effects of smoking on cognitive function 
are complex with acute nicotine consumption improv-
ing smokers’ cognition, and nicotine abstinence decreas-
ing cognition [12]. Longitudinal research has shown that 
lower childhood IQ is associated with increased risk of 
smoking, and smokers have significantly worse cognition 
scores in old age than ex- or never-smokers [13]. There-
fore, public health measures to reduce rates of smoking 
could improve both lung function and cognitive function.
Both cognition and lung function follow life course tra-
jectories, influenced by a combination of genetic and life 
course factors [4]. Genetic determinants of lung devel-
opment and disease are increasingly recognised [31]. 
In addition to shared environmental risk for lung func-
tion and cognitive function, shared genetic risks may be 
found. Genes involved in growth factors and Vitamin A 
regulation have been found to affect lung function. Both 
growth patterns and Vitamin A levels may have a role in 
cognitive function [23, 32]. It may be that genetic plei-
otropy can determine both lung function and cognitive 
trajectories.
Limitations
This study examines the effect of lung function and 
COPD on general cognitive function in general adult 
population. COPD has been shown to be associated with 
general cognitive function, but often more specific pat-
terns of cognitive impairment including attention, mem-
ory, learning and motor function domains [5]. Therefore 
it may be that COPD has does have causal effect on these 
domains, not detected in our general cognitive function 
analysis.
This is comprehensive and robust analysis of causal 
association between lung function and risk of COPD, 
which uses two exposures and MVMR methodology. It 
is worth noting the SNPs in one of our two exposure 
analysis refers to ‘liability’ rather than confirmed diag-
nosis of COPD as no SNP guarantees future COPD, but 
MR is still a valid test of the causal null hypothesis for 
a binary exposure [33]. The mean age in our outcome 
sample was 56, lower than the average age of COPD 
diagnosis. The effects of SNPs for binary traits may be 
underestimated in the outcome sample, as participants 
have not yet developed COPD or its co-morbidities. 
However, the exposure SNPs were discovered and 
validated in large populations that had similar mean 
ages [21, 22]. Therefore the SNPs’ estimated effects on 
COPD liability should be accurate in the outcome pop-
ulation. If the mean age of the outcome population was 
older, it could introduce a survivor bias if a proportion 
of those with the SNPs had died from COPD and could 
not be recruited for the outcome GWAS [34].
One of the proposed mechanisms whereby lung func-
tion and COPD may cause reduced cognition is via 
cerebrovascular pathology [35]. Our outcome popula-
tion excluded those with history of clinical stroke, this 
is unlikely to have excluded the proposed COPD spe-
cific brain changes, but would have excluded those with 
large vessel vascular damage causing changes in cogni-
tive function.
Cognitive function can be correlated to factors that 
distort effect estimates. These include demography, 
(when a populations genetic variance is related to geo-
graphical location), assortative mating (partners are 
chosen due to phenotypes e.g. higher cognitive func-
tion, rather than randomly) and dynastic effects (phe-
notypic expression of parents genotype affects offspring 
phenotype e.g. parents with higher education giving 
educational books to their children) [36]. This can be 
corrected for by using within-family GWAS, a possible 
area for future studies [37]. However, MR studies have 
tended to over-estimate the effect of anthropomorphic 
traits which then attenuate when using within-family 
studies, and in this study we only found weak evidence 
of an anthropomorphic trait having an effect.
The populations used by the GWAS for exposure 
SNP’s only used European ancestry participants. These 
results may therefore not be generalizable to non-Euro-
pean ancestral populations. We did not have a replica-
tion cohort for the SNPs used in the MVMR analysis. 
The effects of the SNPs could have been over estimated 
due to “Winner’s Curse” phenomenon [38]. This occurs 
in GWAS when effect estimates are biased towards the 
SNPs with the strongest association. However, this phe-
nomenon would bias results away from the null.
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Future research
Our outcome GWAS was performed with global cogni-
tive function in the general population as a continuous 
outcome. Much research has focused on whether lung 
function and lung disease causes mild cognitive impair-
ment (MCI) [39]. Normal cognitive function and MCI 
exist on a spectrum, but our study is unable to fully assess 
whether reduced lung function or lung disease causes 
MCI. If a GWAS of MCI becomes available MR could be 
used in future studies.
Our results indicate that lung function alone does not 
causes lower cognition in general population. However, 
lower lung function and lung disease have been shown 
to be associated with reduced cognitive function, but this 
is most likely due to shared risk factors. Research should 
focus on reducing exposure to these shared risk factors 
and optimising the management of co-morbidities in 
those with chronic lung disease.
Conclusion
Our study shows that lung function and COPD do not 
cause reduced cognition in the general population. Pre-
vious observational studies suggesting a causal link were 
probably affected by residual confounding. The observed 
associations between reduced lung function, COPD and 
cognitive function remain important. Research should 
now focus on the management of cognitive impairment 
in these groups, rather than targeting lung function alone 
in order to improve cognition in the general population.
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